Navigation Links
PharmaLeaders: Innovative Mid-Cap Biotechnology Benchmark Report - Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs
Date:4/23/2013

cent pipeline and clinical advancements, along with licensing and acquisition activity, and operations strategy. Lastly, this report provides GlobalData's viewpoint on each company's future revenue outlook, and competitive position within the biotech space.

Scope

- Financial Benchmarking: Report uses GlobalData's proprietary benchmarking methodology to rank 15 innovative biotech companies on 20 different financial metrics
- Pipeline analysis: Tracks pipeline advancements and drug approvals across this peer group over the past 12 months
- Licensing & Acquisition Strategies: Deep discussion on the strategic implications and synergies of recent M&A and deals activity
- Resource Management Strategies: New section created to discuss and analyze the operations and firm utilization of these innovative biotech companies.
- Expert Insight on the corporate strategies of these mid-cap biotech companies seeking a competitive advantage in the pharmaceuticals market place
- Revenue Forecasts: New analysis providing top-line revenue forecast for each company for next six months.

Reasons to buy

- Analyze and track the strategies that these successful biotech companies are using to gain share in an increasingly competitive market
- Understand and benchmark the financial metrics that differentiate certain companies from the pack in terms of revenue performance, cost containment, and firm utilization
- Target novel companies with proprietary technologies to maximize opportunities for strategic investment or partnerships
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Use information as an independent source for your due diligence and transaction strategies.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
2. Innovative MetaMorph® NX Software Shatters Barriers Between Researchers and Image Analysis Goals with Exclusive Visual Workflow
3. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
4. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
5. CMC Biologics Strengthens its Innovative Biomanufacturing Technology Portfolio in Continuous Perfusion Systems
6. FasterCures Spotlights Addario Lung Cancer Medical Institutes Innovative Research Programs
7. ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits
8. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
9. Stanford faculty awarded $2.2 million for innovative energy research
10. Collegiate Inventors Honored for Innovative Science and Technology Advances
11. France & Germany Blood Banking Market: Innovative Technologies and Emerging Business Opportunities in New Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... - Oncothyreon Inc. (NASDAQ: ONTY ) today ... of its Common Stock and Series A Convertible Preferred ... Series A Convertible Preferred Stock is non-voting and convertible ... will be prohibited if, as a result, the holder ... of the Common Stock then outstanding. As part of ...
(Date:9/17/2014)... 17, 2014 A biodegradable polymer ... such as bacteria, fungi, and algae into smaller ... biomass, inorganic compounds, carbon dioxide, and humus in ... base and improved costs, biodegradable polymers are proving ... alternative to conventional polymers. Primary factors that are ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... Mass. , Sept. 17, 2014 ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced that it has been ... and Trademark Office on its unique delivery system ... ) to phagocytic cells for the treatment of ...
Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... 15, 2011 Generex Biotechnology Corporation ( www.generex.com ... the status of the previously announced spinout of ... ). The Company is in the ... several transaction opportunities, including both shell companies and ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... provide an overview of the company,s business strategy at ... the UBS 2011 Global Life Sciences Conference which will ... addition, Geoffrey Nichol, M.B., Ch.B., Sangamo,s executive vice president ...
... Aperion Biologics, Inc. announced that it has reached ... Company,s clinical trial of its Z-Lig™ Anterior Cruciate Ligament ... of the knee. The randomized multicenter study commenced in ... provide safety and performance data in the reconstruction of ...
Cached Biology Technology:Generex Provides Update on Spinout of Antigen Express 2Generex Provides Update on Spinout of Antigen Express 3Generex Provides Update on Spinout of Antigen Express 4Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference 2Aperion Biologics Reaches Midpoint of Enrollment in Z-Lig™ Anterior Cruciate Ligament Reconstruction Medical Device Performance Trial 2
(Date:9/16/2014)... Menopause Society (NAMS) has published its key, evidence-based ... everything from hot flashes to heart disease. The ... for Clinical Care of Midlife Women," was published ... . This is the first, comprehensive set of ... freely available to all clinicians who care for ...
(Date:9/16/2014)... Two Johns Hopkins neuroscientists have discovered the "molecular brakes" ... inner ear cochleas of mice. These "hair cells" translate ... the brain and are interpreted as sounds. If the ... , A summary of the research will be ... Sept. 16. , "The proteins Hey1 and Hey2 act ...
(Date:9/16/2014)... inherit certain traits from our parents that are pre-determined. ... play out by taking certain drugs or better yet, ... team of researchers at the Boston University School of ... research. , Epigenetics regulates gene expression in a ... which prevent permanent mutations or alterations within the gene ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
... world,s top biodiversity hotspot for reptiles and amphibians, according ... from the University of California, Berkeley, Southern Illinois University ... The park, which encompasses lowland Amazonian rain forest, high-altitude ... well known for its huge variety of bird life, ...
... to climate change are being compiled by research groups ... various sources results in different climate projections; hence, the ... arrive at a consensus regarding future climate estimates. ... SIAM Journal on Uncertainty Quantification , authors Matthew ...
... , New Rochelle, NY, February 19, 2014Joseph C. Glorioso, ... devoted much of his research career to developing herpes ... cells. In recognition of his leadership and accomplishments, ... Gene Therapy , a peer-reviewed journal from Mary Ann ...
Cached Biology News:Peru's Manu National Park sets new biodiversity record 2Peru's Manu National Park sets new biodiversity record 3Statistics research could build consensus around climate predictions 2Statistics research could build consensus around climate predictions 3Statistics research could build consensus around climate predictions 4Joseph Glorioso, Ph.D., receives Pioneer Award 2